Anti-NOV (CCN3/IGFBP9) Polyclonal Antibody for IHC-P and ELISA - P48745

Core Product Specifications and Parameters

Biological Background: NOV (CCN3/IGFBP9) Function and Localization

• NOV (CCN3/IGFBP9) is a member of the CCN family of matricellular proteins, functioning as an immediate-early gene involved in proliferation, adhesion, migration, differentiation, and survival. Related references: PMID:12050162, PMID:12695522, PMID:15181016
• It acts as a ligand for integrins (ITGAV:ITGB3, ITGA5:ITGB1) and membrane receptors such as NOTCH1, modulating Notch signaling to inhibit myogenic differentiation. Related references: PMID:12695522, PMID:15611078, PMID:21344378, PMID:12050162
• NOV negatively regulates vascular smooth muscle cell proliferation by upregulating cell-cycle inhibitors CDKN2B and CDKN1A in a TGFB1-independent manner. Related references: PMID:20139355
• It promotes angiogenesis by supporting endothelial cell adhesion, chemotaxis, and survival, and also plays a role in cutaneous wound healing and fibroblast chemotaxis. Related references: PMID:12695522, PMID:15611078
• NOV exhibits anti-inflammatory effects by inhibiting NF-kappaB signaling and reducing monocyte adhesion, and attenuates inflammatory pain through regulation of MMP9, MMP2, and CCL2. Related references: PMID:21063504, PMID:21871891
• The protein is secreted and also localized to the cytoplasm and cell junction gap junctions, with expression in endothelial cells, bone marrow, and thymus. Related references: PMID:21063504
• Post-translational modifications include disulfide bonds, glycosylation, and palmitoylation, and it functions as a growth factor and hormone.
• NOV is essential for hematopoietic stem and progenitor cell function and drives osteogenesis in skeletal stem cells. Related references: PMID:17463287, PMID:38987585

Experimental Guidance and Technical Tips

• The immunogen comprises amino acids 32-357 of human NOV (NP_002505.1), covering the mature protein without the signal peptide, and the polyclonal antibody may recognize multiple epitopes. For IHC-P, optimal antigen retrieval and blocking conditions should be empirically determined.
• Recommended for IHC-P and ELISA applications; if used in other techniques such as WB, validate in the relevant sample system and consider the predicted molecular weight of ~39 kDa.
• Include appropriate positive and negative controls (e.g., human tissue expressing NOV) to confirm staining specificity.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers and research labs with a comprehensive range of IVD raw materials, including validated antibodies, paired antibody sets, and bulk ancillary reagents. For NOV/CCN3 research, we offer polyclonal and monoclonal antibodies optimized for immunohistochemistry and ELISA to support oncology, bone biology, and inflammation studies. Our supply chain ensures consistent lot-to-lot performance and reliable delivery, accelerating your diagnostic development from concept to clinic.